Clinical trial
Phase II/III Randomized, Double-Masked, Trial, to Establish the Safety and Efficacy of Intravitreal Injections of EYE001 (Anti-VEGF Pegylated Aptamer) Given Every 6 Weeks for 54 Weeks, in Patients With Exudative AMD).
NCT00021736 is registered in ClinicalTrials.gov with Eyetech Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II/III Randomized, Double-Masked, Trial, to Establish the Safety and Efficacy of Intravitreal Injections of EYE001 (Anti-VEGF Pegylated Aptamer) Given Every 6 Weeks for 54 Weeks, in Patients With Exudative AMD).
- Lead sponsor
- Eyetech Pharmaceuticals
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- July 31, 2001
- Completion date
- July 31, 2002
- Enrollment
- 540
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.